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Indirect genomic effects on cancer patient survival<p>A nov l methodology is pres nted for detecting and quantifying indirect effects on cancer survival mediated through several target genes of transcription factors in cancer microarray data.</p>
Abstract
In cancer, genes may have indirect effects on patient survival, mediated through interactions with
other genes. Methods to study the indirect effects that contribute significantly to survival are not
available. We propose a novel methodology to detect and quantify indirect effects from gene
expression data. We discover indirect effects through several target genes of transcription factors
in cancer microarray data, pointing to genetic interactions that play a significant role in tumor
progression.
Background
There exists a large literature studying associations between
survival and high throughput gene expression data [1-5].
Also, much work has been done to elaborate pathways and
regulatory networks [6-10]. We have developed a new
method combining survival and pathway analysis technolo-
gies, aiming at a causal understanding of how gene expression
affects survival. This allows us to discover indirect effects of
gene expression on patient survival, mediated through other
genes. To our knowledge, no comparable method exists that
can achieve this. For the first time, we are able to identify in
cancer microarray data significant indirect effects of tran-
scription factors, such as PPAR proteins, E2F1 and MYC, on
survival.
Genome-wide exploration for genes involved in malignant
diseases will enable the development of new approaches in
cancer diagnostics and therapeutics that will revolutionize
the drug discovery field and the development of personalized
medicine [11,12]. Lists of genes predictive for treatment out-
come of various cancers have been presented, and may poten-
tially be used for selecting patients at risk for treatment
failure and aid in clinical decision making. However, the
organization of the prognostic genes into structured, func-
tionally meaningful information is difficult and, currently,
one of the main obstacles limiting the clinical utilization of
microarray data [13,14].
A major challenge in the interpretation of microarray results
is understanding the biological effect mediated by transcrip-
tion factors. These proteins are often key actors in complex
regulatory networks containing many signaling pathways,
and may interact with other prognostic genes. They can have
several modes of interaction with their targets, such as tran-
scriptional activation and/or repression of genes and post-
transcriptional modification of proteins [15,16]. Their effect
can, therefore, be mediated both by changing the expression
level of other genes and through mechanisms undetectable in
gene expression studies. Due to the central role of many tran-
scription factors in controlling the cellular phenotype, these
have been proposed as potential targets for therapeutic inter-
vention [17]. However, transcriptional interaction between
these proteins and other genes makes it difficult to predict the
outcome of such interventions. Elucidation of how the
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to the development of aggressive cancer phenotypes will aid
the design of efficient drugs that interfere with key pathways
of the regulatory network.
Current pathway analysis tools have proved useful for validat-
ing known interactions of transcription factors and proposing
unknown pathways in their regulatory networks [18]. How-
ever, these tools make no use of the important information
represented by patient survival data and are not, therefore,
suitable for exploring direct transcription factor-target rela-
tionships that may have prognostic value. Our aim was to
enable detection, separation, quantification and comparison
of possible direct and indirect effects on survival that are
mediated by transcription factors. We consider a data set with
genes, the expression levels of which are measured using
material from patients. Note that the data consists of both the
gene expression measurements and a data set of regulatory
interactions between genes. A gene has an 'indirect effect' on
survival if its expression influences survival through one or
more other prognostic genes present in the data. A gene has a
'direct effect' on survival if its expression influences survival
and no other gene is found in the dataset through which this
effect is mediated. A direct effect is caused by interactions
that are undetectable in the given gene expression data,
because the effect is mediated either through protein modifi-
cations or by transactivation/repression of genes that are not
associated with survival and/or are not included in the data
set.
We applied the method to the gene expression data of three
previously published cancer studies. In all three cases we
identified several transcription factors with one or more indi-
rect effects on survival, pointing to the interactions of major
importance for the development of an aggressive tumor phe-
notype. Although the indirect effects were always weaker than
the direct effect, they are highly significant and of biological
interest. We further demonstrate that the indirect effect did
not always strengthen the direct effect, but for some genes,
counteracted it, posing fundamental questions about the
effect of therapeutic targeting of transcription factors. Protein
expression, phosphorylation and/or enzymatic activities can
be used alone or together with gene expression in our model,
providing a more comprehensive exploration of the path-
ways. Our method represents a totally new way of utilizing
large scale gene and protein data that may increase our
knowledge of how specific transcription factors contribute to
the progression and treatment outcome of cancers as well as
other diseases.
Results
Hunting for indirect effects
First, we illustrate the results that are obtained with our
method, using the genes PPARD (encoding peroxisome pro-
liferator-activated receptor D) and ADFP (encoding adipose
differentiation-related protein) as an example (Figure 1,
model 2). All details are explained in the subsequent text. We
have gene expression data for both genes from cancer
patients and censored survival data from the same patients. It
is known that expression of PPARD influences expression of
ADFP. An effect of PPARD on survival could, therefore, be
mediated through ADFP. In our terminology, this is an indi-
rect effect of PPARD on survival, through ADFP. Other indi-
rect effects of PPARD, through other genes, could also exist,
and PPARD could also have a direct effect on survival, that is,
an effect that is not mediated through any other genes in our
data set. Using our method, we can discover and quantify the
strengths of such indirect and direct effects. Specifically, we
found that, summed over the first five years, PPARD had a
direct effect on survival of 0.141 (with a 95% bootstrap confi-
dence interval of (0.047, 0.206)), and an indirect effect of
0.048 (95% confidence interval of (0.030, 0.101)). In this
case, all effects are positive, indicated by plus signs on the
arrows in Figure 1. In other cases, the effects can be negative,
indicated by minus signs. Positive effects are harmful
(increase the risk of death), while negative effects are benefi-
cial. Since the bootstrap confidence intervals do not contain
zero, both the direct and indirect effects are significant. The
'total effect' is simply the sum of the direct and indirect
effects. Here, approximately 24% of the total effect is indirect.
We developed a stepwise procedure, generating the candidate
networks, selecting significant genetic interactions, and iden-
tifying the most relevant dynamic path models with indirect
effects.
Survival genes and survival forests
To compile a first list of genes associated with survival, we
used a simple univariate selection procedure: for each gene in
a data set, an additive hazard regression model was estimated
with the gene expression value as the only covariate (Figure
2). The genes were then ranked according to their statistical
significance (p-value), and a set of these top genes, called sur-
vival genes, was considered further. P-values were calculated
using the common test for effects in the additive hazard
model, as described in [19]. Any rule can be used to select sur-
vival genes from the full data set, for example, thresholding
according to p-value or number of genes. More complex mul-
tivariate selection procedures could also be used [5], but in
this context we believe that they would not be advantageous.
Since the aim was to identify genes highly correlated with sur-
vival, we wanted all genes of this type to be retained by the
selection procedure, even if they are correlated to each other.
Stepwise selection or penalized regression methods model
dependence between genes, and hence lead to rankings that
do not have this property. Most importantly, the set of sur-
vival genes must be large enough to ensure a rich survival for-
est in the continuing analysis. We then input the survival
genes into Pathway Studio [8], which generates pathways
involving the survival genes based on public databases and
published literature. The use of Pathway Studio is in no wayGenome Biology 2008, 9:R58
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Dynamic path models for the Dutch breast cancer data set. The top panel shows the thinned survival forest after selecting genetic interactions for which 
an indirect and direct effect likely existed. Black arrows indicate a total of 19 significant interactions. The thinned forest consisted of eight networks. A 
number of dynamic path models were fitted to different sub-networks of these networks: Each connected component, each rooted subtree (that is, each 
gene with all of its descendants), and each interaction separately. For ten models there was at least one significant indirect effect, indicated with rectangles 
of different colors. Below the thinned survival forest, the ten models with at least one significant indirect effect are shown. Interactions with significant 
direct or indirect effects are marked with red arrows. The plus and minus signs on arrows between two genes indicate transcriptional activation and 
repression, respectively, whereas the plus and minus signs on arrows pointing to survival (dN(t)) indicates that poor survival is associated with activation 
and repression of the gene, respectively. For each significant path, the average strength of the direct and indirect effect during the first five years is listed, 
along with a 95% bootstrap confidence interval.
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the hypothesized pathways can be modeled by directed
graphs. We obtained a collection of directed graphs, called a
'survival forest', representing known pathways involving the
survival genes (Figure 2). Only pathways that could be repre-
sented as directed acyclic graphs (DAGs) were selected. Our
method currently does not handle feedback effects, which are
then appropriately simplified. Since our basis was gene
expression data, we considered only transcriptional interac-
tions, meaning that each pathway contained at least one pro-
tein with known transcription factor activity interacting with
one or more other genes by changing their expression level.
Each interaction was then of the form gene A → gene B, which
we write as A → B, representing that the expression of gene A
influences the expression of gene B. The collection of all the
pathways in the survival forest was analyzed further, to find
the significant direct and indirect effects on survival.
Thinning the survival forest for possible indirect effects
Since our purpose was to identify transcription factors with
one or more indirect effects on survival, in addition to direct
effects, we deleted all genes where significant indirect effects
were unlikely. This selection was based on the likelihood of
finding evidence of indirect effects (Figure 2). For each inter-
action A → B the additive hazard regression model with A and
B as covariates and survival as response was fitted to the gene
expression data. We chose the interactions for which both the
effects of A and B on survival were significant at p < 0.05 and
dropped other links. This was done because the interaction A
→ B, for which both A and B influence survival, gives the
potential for an indirect effect of A through B in addition to
the direct effect of A on survival. The selection procedure,
therefore, reduced the survival forest to a collection of inter-
action networks for which the expression of all genes was sig-
nificantly correlated with survival. Thinning also leads to a
computational advantage. This 'thinned survival forest'
formed the basis for the dynamic path modeling.
Selecting dynamic paths with indirect effects
We now searched every network in the thinned survival forest
for significant indirect effects by dynamic path analysis [20]
(in Materials and methods). This led to a further reduction of
the forest, such that it only included networks where indirect
effects were significant (Figure 2).
The analysis was performed on each network separately. The
results depended on which genes of each network were
included in the model. There is a trade-off between accuracy
and power when selecting models. Choosing a large model
reduces the risk of leaving out possible interacting survival
genes. On the other hand, interesting effects may be reduced
in a large model, because covariates can be more correlated
by chance. Hence, we operated systematically. First, a
dynamic path model was fitted to each connected component
of the networks separately. Within a connected component, a
model was fitted for each gene together with all its descend-
ants (if any). In the final stage of this strategy, each pair of
interactions was modeled separately.
For each model, the strength of the individual interactions
was precisely quantified as described in Materials and meth-
ods. These estimated effects can be positive or negative. For
interactions between genes, a positive effect of A → B means
that an increase in the expression of A leads to an increase in
the expression of B, and a negative effect means the opposite.
For an effect from a gene to survival, a positive effect is harm-
ful (increases the risk of death), while a negative effect is ben-
eficial. The unit of the effect is the increase in the death rate
per unit increase of gene expression.
After the models had been fitted, we used bootstrapping to
judge whether the estimated effects were significant. A total
of 1,000 bootstrap replications were used. Because of deaths
and censorings, the set of patients on which the estimation is
based changes over time. The effects can, therefore, be esti-
mated at every time point and change when the population at
risk changes. Hence, the significance of the effects also
changes at each time point. We considered an effect as signif-
icant if the 95% bootstrap confidence interval did not contain
zero after five years, which is a commonly used horizon in
cancer studies. Longer time periods can be used, but estima-
tion becomes less precise due to the lower number of patients
with such long survival times. We selected only models con-
taining at least one significant effect.
Multiple testing
Running a separate test on each genetic interaction created
multiple testing concerns. To address these, we used a per-
mutation approach where the whole selection procedure was
run repeatedly on randomly permuted survival data. In this
way we could assess how many interactions would be found if
the gene expression levels and survival times were completely
unrelated. A total of 1,000 permutations were run for each
data set, and the resulting number of interactions selected
when only generated by chance was compared to the actual
findings, as demonstrated in Table 1 for the data sets analyzed
below.
Confounding
Can confounding misguide our results? What if relevant
genes or interactions were incorrectly omitted from our mod-
els? Figure 3 illustrates this issue. Assume that we would
obtain a significant estimated model, with genes A and B sig-
nificantly associated with survival, and with the interaction A
→ B present in the thinned survival forest (Figure 3a). A has
a direct effect on survival, as well as an indirect effect through
B. Figure 3b illustrates the problem of confounding. U is
another gene, or more generally, a collection of genes. The
gray shading indicates that U is omitted, that is, not a part of
the estimated model. The problem is that the 'common cause'
U will generate, unconditionally on U, a statistical association
between A and survival that is not due to the direct effect of AGenome Biology 2008, 9:R58
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Selecting dynamic path models. This figure shows a description of the dynamic path model selection procedure. A, B, ... represent gene A, gene B, .... 
Arrows indicate interactions between genes or between gene and survival.
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3b, while our estimated model is that of Figure 3a, we produce
biased effects or a false positive. Assume that the data source
of regulatory interactions contains the interactions U → A
and U → B. Then, we argue that the situations in Figure 3b are
unlikely to occur in our methodology, because of the way the
stepwise selection procedure works (Figure 2). To see this,
note that for a confounding gene U to be present, U must have
an effect on survival. But this means that U would have been
one of the 'survival genes' kept in the first step of the selection
procedure, and hence would not be omitted. At least for the
breast cancer data sets, we do have expression measurements
for the majority of genes that could affect survival. Further-
more, the interaction U → A (or U → B) would have remained
after the thinning procedure, since there would be evidence
for both A → survival and U → survival from the data. For
these reasons, it appears unlikely that we would estimate the
model of Figure 3a if any of the models in Figure 3b were true.
In the presence of a confounding gene U, the effects U → A
and U → survival would be discovered, and the correct model
would be estimated. However, it should be pointed out that if
the interactions U → A or U → B are not present in the data
source one is using (that is, if these regulatory interactions are
not known in the literature), then the preceding argument
does not hold. Also, if U is not a gene, but some unmeasured
environmental factor such as smoking, then, as smoking
could affect both gene A (gene B) and survival, the problem of
confounding could arise. But this is a potential problem in
any statistical analysis not controlling for relevant environ-
mental factors, and nothing in our methodology would make
our results more vulnerable than usual to confounding in this
more general sense. Still, care should be taken in the interpre-
tation of our models, and we do not claim to discover 'causal
relations' in the strict sense of the term. The third general
effect of 'missing interactions' is illustrated in Figure 3c. Here,
U is a (set of) omitted mediator(s). In the left panel, there is
an additional path A → U → survival, which is left out of the
models, and the left panel shows a case with a missing inter-
action A → B → U → survival. In fact, this situation is not
problematic: in the situation shown in the left panel, the
direct effect should be defined as the sum of the two paths A
→ survival and A → U → survival, and the indirect effects
should be defined similarly as the sum of the two paths
through B. The reason is simply that the inclusion of omitted
mediators is equivalent to looking at a system in greater detail
(finer resolution), which may always be done, and this does
not invalidate the model defined at a coarser resolution.
Dynamic path model in cancer genomics data
We applied dynamic path analysis on three microarray data
sets containing right-censored survival times for the patients.
In all cases, we estimated cumulative effects after five years;
Table 1
Permutation test
Number of interactions 1 2 3 4 5 6 7 8 9 10 11 Our finding
Dutch data 0.844 0.087 0.036 0.017 0.009 0.003 0.003 0.001 0.000 0.000 0.000 19
Uppsala data 0.698 0.150 0.081 0.032 0.018 0.006 0.006 0.002 0.003 0.002 0.002 7
DLBCL data 0.829 0.095 0.043 0.022 0.004 0.005 0.002 0.000 0.000 0.000 0.000 9
This table shows the probabilities of finding the number of interactions listed in the first line, if survival and gene expression were associated at 
random.
Confounding and omitted mediatorsFigure 3
Confounding and omitted mediators. This figure illustrates issues 
connected to omitted genes/interactions. (a) The assumed estimated 
model, as produced by our method. (b) The problem of confounding. (c) 
Two cases of omitted mediators.
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A
B
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A
B
survival A
B
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U
U
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A
B
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B
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U
U
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(c)Genome Biology 2008, 9:R58
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observation.
Dutch breast cancer data
The Dutch breast cancer data set from the study of van de
Vijver et al. [21] and van Houwelingen et al. [22] consists of
24,885 gene expression values for 295 women with breast
cancer. A total of 175 genetic pair interactions were generated
by Pathway Studio based on the gene list of 1,000 survival
genes. Out of these, the selection procedure resulted in 19
interactions for which an indirect and direct effect likely
existed (Figure 1). This gave a thinned survival forest with
eight networks. The number of 19 interactions is highly signif-
icant, showing the pronounced reliability of the results, since
in the permutation test a single interaction was selected in
844 out of 1,000 permutations, and more than 8 interactions
were never selected (Table 1).
Dynamic path modeling based on the selected genetic inter-
actions of the thinned survival forest resulted in ten models
with at least one significant indirect effect on survival (Figure
1). There were two major types of models. The simple models
involved two genes in the significant subnetwork, a transcrip-
tion factor with a single interacting gene (models 1-6 and 9).
In the complex models with three or more genes in the signif-
icant subnetwork, a transcription factor showed indirect
effects through two genes (models 7 and 8), or two transcrip-
tion factors had an indirect effect through a common gene
(model 10). In the former cases the indirect effect was either
through serially interacting genes (model 7) or genes interact-
ing in parallel with the transcription factor (model 8). Mem-
bers of the peroxisome proliferator-activated receptors
(PPAR) family were involved in all the complex and some of
the simple models, whereas E2F1, MSX2, and MYBL2 were
involved in simple models.
In most cases the indirect effect strengthened the direct one,
leading to a stronger total effect than suggested from the
direct effect. A typical example is shown in model 1, where
activation of PPARD led to a direct effect of 0.178 and an indi-
rect effect of 0.011 through PPARA, resulting in a total effect
of 0.189. This means that a unit increase in the expression of
PPARD implies an increase in the death rate of 0.189 deaths
per year, so here the indirect effect is 5.8% of the total effect
on survival. The indirect effect could, however, also counter-
act the direct effect (models 4 and 9). Hence, repression of
PPARG led to a negative direct effect of -0.068, whereas activa-
tion of PPARG was indirectly associated with poor survival
through ADPF with a positive strength of 0.023 (model 9). The
total effect of PPARG in this model was, therefore, -0.045, still
negative but weaker than expected from the direct effect alone.
For all models that included both a significant direct and a
corresponding significant indirect effect, the indirect effect
was weaker than the direct one, but could still represent a
strength of more than 50% of the indirect effect (range 6-
52%). However, for some models we found indirect effects
without corresponding significant direct effects: the indirect
effect of PPARD in model 7, the indirect effect of PPARA in
model 8 and the indirect effect of PPARG in model 10, sug-
gesting that the indirect effects were strong compared to the
direct ones in these cases.
We have reported estimated cumulative effects after five
years. In fact, all our estimates are available in continuous
time. To illustrate this, Figure 4 shows the time course devel-
opment of model 2 of Figure 1, containing the two genes
PPARD and ADFP. From these cumulative plots, we read that
the indirect effect (Figure 4a) is positive and stable for the
Time evolution of the dynamic path model containing PPARD and ADFPF gur  4
Time evolution of the dynamic path model containing PPARD and ADFP. 
This figure shows the time evolution of the model from model 2 of Figure 
1. (a) The cumulative indirect effect of PPARD (through ADFP) on survival, 
and (b) the cumulative direct effect of PPARD on survival. The indirect and 
direct effects are estimated as explained in Materials and methods; see 
particularly equations 3 and 4 for details of the calculations. The indirect 
effect is approximately constant for the first six years, and zero thereafter 
(recall that the plots are cumulative). Similarly, the direct effect remains 
positive and stable for the first three years, and then becomes zero. As 
expected, confidence intervals become wider over time, due to fewer 
remaining patients. Based on these plots, the use of a five year horizon 
seems reasonable.
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(Figure 4b) is stably positive for the first three years, and then
vanishes. Both plots show widening confidence intervals over
time, due to fewer remaining patients alive and under
observation.
Uppsala breast cancer data
The Uppsala breast cancer data set from Miller et al. [23] con-
sists of 44,928 gene expression measurements for 251 breast
cancer patients. A total of 380 genetic interactions were gen-
erated based on an input list of 2,000 survival genes. Seven
interactions in six networks were chosen by the selection pro-
cedure (Figure 5). The number of interactions was much
higher than expected by chance alone (Table 1), suggesting
the selected interactions are highly reliable. The genetic inter-
action STAT5A → PPARA was among those selected, as in the
case of the Dutch breast cancer data set (Figure 1).
Three models with at least one indirect effect on survival were
found by the dynamic path analysis (Figure 5). All models
also included a significant direct effect. There was one com-
plex model, where both AR and FN1 had an indirect effect
through VCAM1 (model 11), and two simple models, where
NR2F6 and STAT5A showed indirect effects through REN
and PPARA, respectively (models 12 and 13). The indirect
effect of NR2F6 strengthened the direct one (model 12),
whereas for AR, FN1 and STAT5A, a weakening of the direct
effect occurred (models 11 and 13). The strength of the indi-
Dynamic path models for the Uppsala breast cancer data setFigure 5
Dynamic path models for the Uppsala breast cancer data set. The top panel shows the thinned survival forest after selecting genetic interactions for which 
an indirect and direct effect likely existed. Black arrows indicate a total of seven significant interactions. The thinned forest consisted of six networks. A 
number of dynamic path models were fitted to different sub-networks of these networks: each connected component, each rooted subtree (that is, each 
gene with all of its descendants), and each interaction separately. For seven models there was at least one significant indirect effect, indicated with 
rectangles of different colors. Below the thinned survival forest, the seven models with at least one significant indirect effect are shown. Interactions with 
significant direct or indirect effects are marked with red arrows. The plus and minus signs on arrows between two genes indicate transcriptional activation 
and repression, respectively, whereas the plus and minus signs on arrows pointing to survival (dN(t)) indicate that poor survival is associated with 
activation and repression of the gene, respectively. For each significant path, the average strength of the direct and indirect effect during the first five years 
is listed, along with a 95% bootstrap confidence interval.
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AR -> dN(t):
0.023 (0.010, 0.044)
AR -> VCAM1 -> dN(t):
-0.006 (-0.020, -0.005)
FN1 -> dN(t):
-0.032 (-0.100, -0.028)
FN1 -> VCAM1 -> dN(t):
0.008 (0.003, 0.027)
NR2F6 -> dN(t):
-0.017 (-0.031, -0.014)
NR2F6 -> REN -> dN(t):
-0.004 (-0.007, -0.001)
STAT5A -> dN(t):
0.053 (0.041, 0.108)
STAT5A -> PPARA -> dN(t):
-0.005 (-0.017, -0.000)
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Diffuse large B-cell lymphoma data
The diffuse large B-cell lymphoma (DLBCL) data set from
[24] contains 7,399 gene expression measurements of 240
patients with DLBCL. Based on a gene list of 1,000 survival
genes, 385 genetic interactions were generated. Nine of these
were chosen by the selection procedure (Figure 6), which
were much higher than expected by chance alone (Table 1).
The thinned survival forest consisted of eight networks.
Four dynamic models with at least one significant indirect
effect were found (Figure 6). All models were simple, consist-
ing of two genes, and in two cases the direct effect was not sig-
nificant (models 16 and 17). Both strengthening and
counteracting indirect effects were found. The direct effect of
MYC (0.024) was strengthened by the indirect effect caused
by repression of GAS1 (0.003), increasing the total effect of
MYC to 0.027 (model 15). The direct effect of CCL3 (0.027),
on the other hand, was counteracted by the negative indirect
effect through CCR5 (-0.016), resulting in a total effect of
0.011 (model 14). The indirect effect of MYC and CCL3 had
strengths of 59% and 13% of the direct effect, respectively.
Discussion
We have developed a statistical tool based on dynamic path
modeling of gene expression data to detect and quantify indi-
rect effects of genes on survival. The use of the additive, rather
than multiplicative, hazard model for regression of survival
data onto covariates enabled separation of direct and indirect
effects in the dynamic path model [20]. By use of permutation
Dynamic path models for the DLBCL data setFigure 6
Dynamic path models for the DLBCL data set. The top panel shows the thinned survival forest after selecting genetic interactions for which an indirect and 
direct effect likely existed. Black arrows indicate a total of nine significant interactions. The thinned forest consisted of eight networks. A number of 
dynamic path models were fitted to different sub-networks of these networks: each connected component, each rooted subtree (that is, each gene with all 
of its descendants), and each interaction separately. For ten models there was at least one significant indirect effect, indicated with rectangles of different 
colors. Below the thinned forest, the ten models with at least one significant indirect effect are shown. Interactions with significant direct or indirect 
effects are marked with red arrows. The plus and minus signs on arrows between two genes indicate transcriptional activation and repression, 
respectively, whereas the plus and minus signs on arrows pointing to survival (dN(t)) indicate that poor survival is associated with activation and repression 
of the gene, respectively. For each significant path, the average strength of the direct and indirect effect during the first five years is listed, along with a 95% 
bootstrap confidence interval.
CCL3 -> dN(t):
0.027 (0.026, 0.068)
CCL3 -> CCR5 -> dN(t):
-0.016 (-0.035, -0.007)
MYC -> dN(t):
0.024 (0.013, 0.053)
MYC -> GAS1 -> dN(t):
0.003 (0.002, 0.010)
DAXX -> ATRX -> dN(t):
-0.010 (-0.028, -0.002)
RUNX3 -> CD4 -> dN(t):
-0.018 (-0.041, -0.007)
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interactions. Moreover, all possible path models were
considered in a systematic way to ensure that all significant
effects were detected. Based on three publicly available
microarray data sets, we found evidence for significant indi-
rect effects of many transcription factors associated with the
survival of cancer patients. Although our findings are clearly
data dependent and incomplete, since the identification of
effects was based on known transcriptional interactions, they
demonstrate how novel information of transcription factor-
target interactions and their importance for survival can be
obtained with our method. Extending our knowledge of tran-
scriptional interactions may, therefore, increase the number
of indirect effects detected, even based on the same expres-
sion data.
Confounding represents a persistent danger in studies like
ours. We have argued that our method is robust with respect
to the most important possible pitfalls. The results are
guarded against omitted mediators. Omitted common causes
can confound direct and indirect effects, but we have argued
that a genetic origin of these is unlikely.
The regulatory networks of many of the transcription factors
with indirect effects in our work, such as the PPAR proteins,
E2F1, MYC, and RUNX3, are highly complex with numerous
interconnected genes and feedback loops [25-29]. Activation
of these pathways collectively promotes tumor growth and
progression, although expression of the individual members
of the pathways is not necessarily associated with survival.
The dynamic path models are simple compared to the entire
network of the transcription factors, showing that only a few
of the interactions are associated with survival in our data. By
finding significant indirect effects, we identified key interac-
tions, pointing to the most important pathways. Moreover,
the quantitative information of these effects indicates to what
extent they counteract or strengthen the direct effect. Note
that while the absolute values of the coefficients can be
directly compared within each of the data sets, these values
are not comparable between data sets, since the data sets are
not standardized to a common scale. However, relative val-
ues, presented as the ratio between the indirect and direct
effect or the indirect and total effect can be compared both
within and between studies. The indirect effects contributed
significantly to the total effect, and their identification may,
therefore, be useful for understanding the role of transcrip-
tion factors in the development of aggressive tumor
phenotypes.
PPARA, PPARD, and PPARG were involved in many of the
indirect effects identified in breast cancer. These proteins are
members of the nuclear receptor family and are active in the
regulation of lipid metabolism, energy balance,
inflammation, and atherosclerosis through interactions with
numerous genes [25,30]. The participation of these proteins
in the most complex dynamic path models was therefore
plausible. The indirect effects were mainly mediated through
proteins involved in lipid metabolism, such as ADFP [31],
phospholipid transfer protein [32], and angiopoietin-like
protein 4 [33], where the strongest one was the indirect effect
of PPARD mediated by ADFP. A major role of the PPAR pro-
teins in the development of aggressive breast cancers is,
therefore, probably to deregulate lipid metabolism through
interactions with these proteins. Other transcription factors
with indirect effects in breast cancer were E2F1 and STAT5A,
which are essential in the regulation of tumor growth and
apoptosis [26,27]. Their indirect effects were mediated
through BBC3 (E2F1), RAD51 and PPARA (STAT5A), sug-
gesting that the interaction of E2F1 and STAT5A with these
proteins contributed significantly to their effect on survival.
Of note is the apparent inconsistency between the two breast
cancer data sets with respect to the direct effect of STAT5A:
Repression of STAT5A was associated with poor survival in
the Dutch data set, whereas activation of the same protein
correlated with poor survival in the Uppsala data set. We
speculate that this inconsistency could be due to some intrin-
sic difference in the two populations; for example, patients
could be in different stages of the disease for each data set.
MYC and RUNX3, which are regulators of cellular processes
such as proliferation and differentiation [28,29], were among
the transcription factors with indirect effects in lymphomas.
MYC had an indirect effect through the cell cycle inhibitory
gene GAS1, consistent with previous studies indicating that
GAS1 repression is important for MYC-induced promotion of
cell growth [34]. RUNX3 showed an indirect effect through
the T-cell antigen CD4, which is a marker for thymocyte dif-
ferentiation. RUNX3 is required for silencing of CD4 [35],
and our results suggest that this silencing plays a significant
role in RUNX3-induced progression of lymphomas.
Many of the transcription factors with indirect effects, includ-
ing PPARG, E2F1, STAT5A, and MYC, have been suggested as
targets for cancer therapy [36-40]. The numerous interac-
tions of these transcription factors make the outcome of such
targeted therapy difficult to predict. Our work indicates that
indirect effects of transcription factors can counteract and
thereby diminish the direct effect. This was the case for
PPARG, STAT5A, and CCL3 with their indirect effects
through ADFP, RAD51, and PPARA, respectively. Such coun-
teracting indirect effects may present severe therapeutic side
effects, and caution should therefore be taken before these
transcription factors are used as targets. For other transcrip-
tion factors, such as E2F1 and MYC, all indirect effects
strengthened the direct ones and led to a strong total effect,
suggesting that these are more suitable as therapeutic targets.
Hence, knowledge of the indirect effects may lead to a better
understanding of how targeted therapies involving transcrip-
tion factors will influence the survival of cancer patients, and,
therefore, be helpful for target selection. Moreover, a useful
strategy may be to develop compound drugs that target
groups of genes simultaneously, to counteract undesired indi-Genome Biology 2008, 9:R58
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pathways not associated with survival, and therefore not
considered here, may induce other side effects that have to be
considered in the design of the targeted therapy.
Conclusion
Dynamic path analysis of large scale gene expression data
provides reliable quantification of indirect effects of
transcription factors on survival. An improved picture of how
transcription factors mediate their effect on survival can
therefore be obtained. This may lead to a more precise predic-
tion of the effect of new therapeutics targeting transcription
factors and the need to develop complex mixture genetic ther-
apies. Instead of survival, other time-to-event data can be
considered in our model, for example, time to relapse of
advanced disease. The method can be applied widely and
handle other data sets, such as protein phosphorylation data.
In such cases, interactions between phosphorylating proteins
and their targets will be considered. Gene and protein data
can also be included in the same analysis, providing a more
comprehensive analysis of pathways.
Materials and methods
Path analysis and graphical models
The basic idea of graphical modeling is to represent the rela-
tions between variables in a graph with vertices and edges
connecting vertices [41]. Vertices represent variables, and
there is an edge between two vertices if the corresponding
variables are related. The type of relation varies with the spe-
cific scientific context and can represent, for example,
translational pathways. We focus on DAGs. In a 'directed
graph' the edges are directed from one vertex to another. A
'path' is a list of vertices connected along directed edges. A
'directed cycle' is a path of edges beginning and ending in the
same vertex, representing a feedback control system. Such
regulatory systems are not handled by our method. A directed
graph is a DAG if it has no directed cycles.
Each vertex of a DAG represents a random variable Xi, where
i = 1,...,n and n is the number of vertices. In our application, i
is a gene, Xi is a gene expression measurement, and the DAG
represents a regulatory network with several signaling path-
ways. The edges are interactions between the genes. Infor-
mally, there is an edge from Xj to Xh if Xj directly influences
Xh, that is, if the expression of gene j influences the expression
of gene h in some way. Relationships between variables are
assumed to be linear. A 'path model' for (X1,...,Xp) is defined
by letting
where the εj are independent and identically distributed
model error terms with expectation zero and variance σ2 (we
do not need the assumption that these are normally
distributed). The γhj are called 'path coefficients'. The associ-
ated 'path diagram' is a DAG G with an edge from Xh to Xj if
and only if γhj ≠ 0.
For a vertex Xj, the 'parents' of Xj are defined as the set of Xh
for which there is an edge from Xh pointing to Xj. Because of
the linear structure of equation 1, the path coefficients γhj can
be estimated by recursively regressing each variable onto its
parents using ordinary least squares regression.
The additive hazard regression model
The additive hazard model [19,42] is a model for regression of
censored survival data onto (possibly time-dependent) cov-
ariates. The model is an alternative to the proportional
hazards model [43], which is a multiplicative model. The
additive structure of the model is crucial for separating the
direct genetic effects from the indirect ones in the dynamic
path analysis.
The outcome of interest is, for our purpose, a counting proc-
ess Ni(t) indicating whether death has been observed to occur
within time t for individual i (such that Ni(t) = 1 if death has
occurred at or before time t; Ni(t) = 0 otherwise). We use
informally dNi(t) for the possible change in the counting
process in the infinitesimal time interval [t, t + dt) and denote
by Ft- all information (on deaths, censorings, covariates, and
so on) until just before time t. The intensity process is then
defined as:
λi(t) = Prob(dNi(t) = 1|Ft-).
Letting Ri(t) be the at-risk indicator for individual i (R(t) = 1
if individual i is observed at time t, R(t) = 0 otherwise), the
intensity process may be written as:
λi(t) = Ri(t)αi(t)
where αi(t) is the hazard rate. If Xi1,...,Xip are p covariates for
individual i, the additive regression model takes the form:
αi(t) = β0(t) + β1(t)Xi1 + ... + βp(t)Xip,
where the βj(t) are arbitrary regression functions. We may
interpret β0(j) as a baseline hazard, while βj(t) is the excess
risk at t per unit increase of Xij for j = 1,...,p. Estimation is
based on the cumulative regression functions
 Estimation of the Bj(t) is easily carried out
using a least squares procedure [19,20,42].X X j pj j hj h j
h
j
= + + =
=
−∑γ γ ε0
1
1
2 3; , ,..., ; (1)
B t sj j
t
( ) ( ) .= ∫ β ds0Genome Biology 2008, 9:R58
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A dynamic path diagram [20] is a DAG where the vertex set is
partitioned into a 'covariate set' Vc = {X1, X2,..., Xp}, here con-
sisting of all genes in the network, and an outcome variable,
which here is dN(t). We do not allow edges pointing from the
outcome to a covariate.
Estimation in the dynamic path model is done by recursive
regressions. Within the covariate set Vc(t) we are back to
classical path analysis, and each covariate is regressed onto
its parents by least squares. The survival outcome is regressed
onto its parents in the graph using the additive hazard
regression model. Estimation is carried out repeatedly, each
time information changes on covariates (if covariates are time
dependent), deaths or censorings.
Using the dynamic path modeling framework, total effects
can be decomposed into direct and indirect effects. A direct
effect is an effect that is transmitted through a single edge in
the graph to the outcome, while an indirect effect is working
through a path of length greater than one (Figure 7). There
may be several indirect effects of a gene on the outcome.
More precisely, the direct and indirect effects of a covariate Xh
on the (survival) outcome dN(t) are defined as follows. Let
there be r indirect paths from Xh to dN(t), and denote these by
P1,P2,...,Pr. Let the indirect path Pi be of the form:
where wi is the length of the path. The strength of the indirect
effect of Xh on dN(t) is then given by:
where we let ind(Xh → dN(t)) = 0 if r = 0, that is, if there are
no indirect paths, and i1 = h. The definition states that the
strength of the indirect effect is the sum over all indirect paths
of the products of regression coefficients along each path. The
strength of the direct effect dir(Xh → dN(t)) on dN(t) is βh(t),
so the strength of the total effect is given by the sum of βh(t)
and the expression for ind(Xh → dN(t)) above (Figure 7). To
quantify the strength of the indirect, direct and total effects,
we simply plug estimated regression functions  and
 into the formulas above. Since each individual time
point can be rather noisy, we estimate 'cumulative' direct/
indirect effects to improve stability. That is, for ordered event
times T1 <T2 < ..., the estimated cumulative indirect effect at
time t is:
the estimated direct effect is:
and the total effect is the sum of equations 3 and 4. An exam-
ple of an indirect and a direct effect estimated in this manner
is plotted in Figure 4, which shows the results from one of the
models estimated from the Dutch data set. In our data, cov-
P X X X X X N ti h i i i iwi
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The dynamic path model with direct and indirect effectsFigure 7
The dynamic path model with direct and indirect effects. This figure shows 
a dynamic path model with four covariates (genes) X1,X2,X3 and X4 
illustrating how the strength of the direct and indirect effect of X1 on 
survival dN(t) is calculated. Interactions between the covariates are shown 
as arrows (edges). Each γij(t) is an ordinary least squares regression 
coefficient at time t, and each βj(t) is an additive hazard regression 
coefficient at time t. The strength of the direct effect of X1 on dN(t) is 
given by β1(t). There are two indirect paths from X1 to dN(t): one through 
X2 and one through X3 and X4. The strength of the indirect effect of X1 on 
dN(t) is therefore given by γ12(t)β2(t)+γ13(t)γ34(t)β4(t). The strength of the 
total effect is the sum of the strength of the direct and indirect effect, that 
is, β1(t)+γ12(t)β2(t)+γ13(t)γ34(t)β4(t).
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functions are time dependent, since the patient population at
risk changes over time.
Confidence intervals of the estimated effects can be calculated
using non-parametric bootstrap [44], sampling randomly
from the set of all individuals. We have used 1,000 bootstrap
replications in our calculations. The percentile method was
used for calculating confidence intervals.
Computation
All computations were carried out using R [45], an open
source language and environment for statistical computing
and graphics. The additive hazard regression analysis was
done using the freely available R package addreg [46]. An R
package implementation of our approach is available at [47].
Ordinary linear regression was done using the built-in R func-
tion lm. Pathways were generated using Pathway Studio [8].
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